SKIN CANCER DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Skin Cancer Drugs Market, By Drug Type (Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormone Therapy Drugs and Others (Photodynamic Therapy, Cryotherapy and Others)), By Cancer Type (Basal cell carcinoma, Squamous cell carcinoma, Melanoma and Others (Kaposi\'s sarcoma, Mycosis fungoides and Others)), By Route of Administration (Topical, Oral, Injectable and Others (Surgical procedures, radiation therapy and Others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Recent Developments:

New product launches:

On March 22, 2023, Incyte, a U.S. based multinational pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)
In 2021, Regeneron Pharmaceuticals, Inc., a U.S. basedbiotechnology company and Sanofi, a multinational pharmaceutical and healthcare company, announced that the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the first immunotherapy treatment indicated for patients with advanced basal cell carcinoma (BCC), previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate. Full approval was granted for patients with locally advanced BCC and accelerated approval was granted for patients with metastatic BCC.

In June 2020, Regeneron Pharmaceuticals, a biotechnology company and Sanofi, multinational pharmaceutical and healthcare company gained U.S. FDA approval for Libtayo (cemiplimab-rwlc), a PD-1 inhibitor for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). It significantly improved overall survival in advanced NSCLC patients.

Acquisition and partnerships:

In 2022, Merck, a science and technology company, acquired cancer drug developer Imago BioSciences for US$1.35 billion. The acquisition strengthens Merck’s hematology portfolio with Imago BioSciences’ investigational candidate IMG-7289, an orally available lysine-specific demethylase 1 (LSD1) inhibitor being evaluated for myeloproliferative neoplasms.
In 2017, Bristol Myers Squibb, a specialty biopharmaceutical company, entered into a clinical trial collaboration with AbbVie to evaluate the combination of Bristol Myers Squibb's PD-1 inhibitor Opdivo (nivolumab) with AbbVie's Navitoclax in patients with advanced solid tumors. The collaboration will boost their oncology clinical development programs.